Get the Stockscreener App
29.55
2.53%
0.73
Enovis Corp stock is traded at $29.55, with a volume of 1.00M.
It is up +2.53% in the last 24 hours and down -4.37% over the past month.
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
See More
Previous Close:
$28.82
Open:
$30.08
24h Volume:
1.00M
Relative Volume:
0.70
Market Cap:
$1.69B
Revenue:
$2.15B
Net Income/Loss:
$-809.46M
P/E Ratio:
-2.1183
EPS:
-13.95
Net Cash Flow:
$-38.98M
1W Performance:
+3.90%
1M Performance:
-4.37%
6M Performance:
-32.67%
1Y Performance:
-33.54%
1-Day Range:
$29.46
$30.31
1-Week Range:
$28.07
$30.31
52-Week Range:
$25.46
$49.83
Enovis Corp Stock (ENOV) Company Profile
Name
Enovis Corp
Sector
Industry
Phone
(302) 252-9160
Address
2711 CENTERVILLE ROAD, WILMINGTON
Compare ENOV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENOV
Enovis Corp
|
29.55 | 1.65B | 2.15B | -809.46M | -38.98M | -13.95 |
|
ABT
Abbott Laboratories
|
131.75 | 225.01B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.17 | 154.32B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.91 | 144.71B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.02 | 117.85B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.26 | 45.90B | 5.69B | 1.41B | 577.90M | 6.95 |
Enovis Corp Stock (ENOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Jun-13-24 | Initiated | JP Morgan | Neutral |
| Feb-13-24 | Initiated | Stephens | Overweight |
| Jan-22-24 | Initiated | UBS | Buy |
| Jan-03-24 | Initiated | William Blair | Outperform |
| Dec-15-23 | Reiterated | Needham | Buy |
| Oct-20-23 | Initiated | ROTH MKM | Buy |
| Jun-26-23 | Initiated | Needham | Buy |
| May-12-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-11-22 | Initiated | Goldman | Buy |
| Sep-12-22 | Initiated | Canaccord Genuity | Buy |
| Sep-12-22 | Initiated | Evercore ISI | Outperform |
| Jun-28-22 | Initiated | Argus | Hold |
| Jun-27-22 | Resumed | Loop Capital | Buy |
| Jun-16-22 | Initiated | Wells Fargo | Equal Weight |
View All
Enovis Corp Stock (ENOV) Latest News
Executive Vice President of Strategy & Business Development of Enovis Daniel Pryor Buys 9.3% More Shares - Yahoo Finance
Enovis price target lowered to $58 from $70 at Canaccord - MSN
Enovis Corporation to Announce Q2 2025 Results via Investor Call and Webcast - MSN
Enovis Shares Rise After Executive Buys 10,000 Shares - MarketScreener
Is Enovis Corporation’s ROIC above industry averageQuarterly Trade Review & AI Forecasted Stock Moves - thegnnews.com
Will Enovis Corporation benefit from AI trendsJuly 2025 Outlook & Technical Buy Zone Confirmations - thegnnews.com
Top Executive Makes Bold Move with Major Enovis Stock Purchase - TipRanks
Sector Leaders Rotate Capital Into Enovis CorporationWeekly Trend Summary & Weekly Chart Analysis and Trade Guides - newsyoung.net
Enovis: Strategic Positioning and Growth Potential Justify Buy Rating - TipRanks
Enovis (ENOV) Raises 2025 Guidance Despite Wider Losses Is Management Signaling a Strategic Shift? - simplywall.st
The Top 5 Analyst Questions From Enovis’s Q2 Earnings Call - Yahoo Finance
Enovis to Present at Three Upcoming Investor Conferences - MSN
Stocks Surge Amid Fed Interest Rate Speculation: Tandem Diabetes, Enovis, Dentsply Sirona, Centene, and Molina Healthcare Among Winners - AInvest
Tandem Diabetes, Enovis, Dentsply Sirona, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know - TradingView
Tandem Diabetes, Enovis, Dentsply Sirona, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know | FinancialContent - FinancialContent
UBS Lowers PT on Enovis Corporation (ENOV) to $57 From $65, Keeps a Buy Rating - MSN
DENTSPLY SIRONA, Replimune Group, and Enovis Analysts Maintain Neutral Ratings - AInvest
Teleflex, Envista, Enovis, UnitedHealth Shares Surge Amid Positive Inflation Data - AInvest
Moderna, Teleflex, Envista, Enovis, and UnitedHealth Shares Are Soaring, What You Need To Know - TradingView
12 Best Medical Device Stocks to Buy According to Analysts - Insider Monkey
Full technical analysis of Enovis Corporation stockTop Stock Picks with Forecast Accuracy - Newser
Forecasting Enovis Corporation price range with options dataMomentum Stocks with Breakout Potential - Newser
Is Enovis Corporation meeting your algorithmic filter criteriaEntry Zone Watchlist With Momentum Focus - Newser
How to recover losses in Enovis Corporation stockMulti-Bagger Detection with Trend Tools - Newser
Will Enovis Corporation outperform the marketRisk Aware Trading Ideas with Alert Levels - Newser
Enovis Reports Strong Growth Amid Challenges, Raises Guidance - AInvest
Enovis Corporation Reports Strong Growth Amid Challenges - TipRanks
Enovis Corp's December 2026 Options Begin Trading - AInvest
Quantitative breakdown of Enovis Corporation recent moveFree AI Powered High Return Stock Calls - Newser
Using Python tools to backtest Enovis Corporation strategiesFree Swing Trading Plan With Smart Signals - Newser
How to interpret RSI for Enovis Corporation stockFast Entry Strategy with Price Prediction - Newser
Order flow analysis tools used on Enovis CorporationFree Real Market Momentum Signal Generator - Newser
Enovis raises 2025 revenue guidance to $2.275B amid CEO transition and product momentum - MSN
What institutions are buying Enovis Corporation stock nowWeekly Price Target Forecast and Alerts - Newser
What does recent volatility data suggest for Enovis CorporationInvestment Life Cycle Planning Summary - Newser
Tick level data insight on Enovis Corporation volatilityInvestment Roadmap for High Potential Stocks - Newser
Needham & Company LLC Cuts Enovis (NYSE:ENOV) Price Target to $49.00 - Defense World
Enovis Delivers 7% Sales Growth in Q2, Raises Full-Year Outlook - MSN
Earnings Release: Here's Why Analysts Cut Their Enovis Corporation (NYSE:ENOV) Price Target To US$53.40 - Yahoo Finance
Enovis Corporation (NYSE:ENOV) Q2 2025 Earnings Call Transcript - MSN
Wells Fargo Maintains Enovis Corp(ENOV.US) With Buy Rating, Cuts Target Price to $41 - 富途牛牛
Does Enovis Corporation stock pay reliable dividendsFree Growth Based Investment Plan Guidance - Newser
Enovis Corporation Reports Q2 2025 Financial Results - The Globe and Mail
Enovis 2025 Q2 Earnings Net Loss Widens Sharply - AInvest
Enovis' Q2 2025: Unraveling Contradictions in Recon Growth, Market Dynamics, and Financial Strategy - AInvest
Canaccord Genuity Adjusts Price Target for Enovis (ENOV) to $58. - GuruFocus
Enovis: UBS maintains Buy rating, lowers PT to $57 from $65. - AInvest
Enovis to Attend Key Investor Conferences in August and September - AInvest
Enovis (ENOV) Raises Revenue Guidance but Net Loss Widens Could Profitability Take Priority Next? - simplywall.st
Enovis Corp Inc. (ENOV) Price Performance and Its Relation to the Tech Industry - investchronicle.com
Enovis' Strategic Investor Engagement and Institutional Sentiment Shifts: A Blueprint for Medical Tech Resilience - AInvest
Enovis Corp Stock (ENOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.74%
0.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):